All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
How do you think transplant eligible high-risk multiple myeloma should be managed after induction?
Featured:
Ben DermanThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ben Derman, University of Chicago Medical Center, Chicago, US answers the question: How do you think transplant eligible high-risk multiple myeloma should be managed after induction?
Ben Derman discusses the treatment options for transplant eligible patients who have completed induction therapy. He talks about the results from multiple trials such as the STAMINA trial, that has transplantation as a treatment arm. Ben Derman also discusses the results from the FORTE trial, EMORY trial, the Myeloma XI study, and the IFM-2009 and explains the patient outcomes in each study.
How do you think transplant eligible high-risk multiple myeloma should be managed after induction?
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?